On November 15, 2024, Cardio Diagnostics Holdings, Inc. conducted its annual meeting of stockholders, with approximately 55.51% of eligible shares represented. During the meeting, stockholders voted on four key proposals. The first proposal resulted in the election of seven directors to the board, with Meeshanthini Dogan, Ph.D., and other nominees receiving a majority of the votes. The second proposal, which was approved, allows the Board of Directors to effect a reverse stock split at their discretion within a year. The third proposal, also approved, permits the future issuance of shares amounting to 20% or more of the outstanding Common Stock in non-public transactions, as per Nasdaq rules. Lastly, the ratification of Prager Metis CPA’s LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was confirmed. The meeting's outcomes are detailed in the company's definitive proxy statement filed on October 4, 2024.

On November 15, 2024, Cardio Diagnostics Holdings, Inc. conducted its annual meeting of stockholders, with approximately 55.51% of eligible shares represented. During the meeting, stockholders voted on four key proposals. The first proposal resulted in the election of seven directors to the board, with Meeshanthini Dogan, Ph.D., and other nominees receiving a majority of the votes. The second proposal, which was approved, allows the Board of Directors to effect a reverse stock split at their discretion within a year. The third proposal, also approved, permits the future issuance of shares amounting to 20% or more of the outstanding Common Stock in non-public transactions, as per Nasdaq rules. Lastly, the ratification of Prager Metis CPA’s LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was confirmed. The meeting's outcomes are detailed in the company's definitive proxy statement filed on October 4, 2024.